Business Wire09.21.18
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., has appointed Robert J. Marshall, Jr. as chief financial officer and treasurer, effective Sept. 24. Marshall succeeds Jack Crowley, who will continue with the company in a full-time advisory role until Sept. 28 and will work with Marshall to ensure a smooth transition.
Marshall brings to the company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining the company, Marshall spent 16 years with Zimmer Biomet Holdings Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including vice president, Investor Relations, and corporate treasurer, and most recently as vice president, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Marshall worked for Brown & Williamson Tobacco, a subsidiary of British American Tobacco plc., in Louisville, Ky., where he held several positions of increasing responsibility.
“Bob’s financial acumen and extensive experience in M&A, capital markets and investor relations make him an ideal fit as we look to grow our business and deliver long-term sustainable growth and profitability. He has particularly strong transactional expertise, which will be useful as we look to grow both organically and through future potential acquisitions,” said Mary Anne Heino, president and CEO of the company. “We thank Jack for his valued service to the company over the past eight years, and we wish him well in his future endeavors.”
Marshall has a master's degree in business administration from Indiana University, South Bend, and a bachelor's degree in business administration - finance from the University of Notre Dame. He also holds the CFA designation.
Marshall said, “I am excited to join Lantheus as it enters its next phase of growth. I look forward to working with my new colleagues and employing my experience to help the company continue its strong performance record, optimize its balance sheet, execute on strategic transactions and commercialize products.”
Crowley said, “I am thankful for being part of the Lantheus team that has both grown the company into one of the market leaders it is today and positioned it well for its next stage of growth. I am confident the company is in a strong position moving forward.”
Lantheus Holdings Inc. is the parent company of LMI, a developer, manufacturer, and commercializer of diagnostic imaging agents and products. LMI provides a portfolio of products, including the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The company is headquartered in North Billerica, Mass., with offices in Puerto Rico and Canada.
Marshall brings to the company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining the company, Marshall spent 16 years with Zimmer Biomet Holdings Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including vice president, Investor Relations, and corporate treasurer, and most recently as vice president, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Marshall worked for Brown & Williamson Tobacco, a subsidiary of British American Tobacco plc., in Louisville, Ky., where he held several positions of increasing responsibility.
“Bob’s financial acumen and extensive experience in M&A, capital markets and investor relations make him an ideal fit as we look to grow our business and deliver long-term sustainable growth and profitability. He has particularly strong transactional expertise, which will be useful as we look to grow both organically and through future potential acquisitions,” said Mary Anne Heino, president and CEO of the company. “We thank Jack for his valued service to the company over the past eight years, and we wish him well in his future endeavors.”
Marshall has a master's degree in business administration from Indiana University, South Bend, and a bachelor's degree in business administration - finance from the University of Notre Dame. He also holds the CFA designation.
Marshall said, “I am excited to join Lantheus as it enters its next phase of growth. I look forward to working with my new colleagues and employing my experience to help the company continue its strong performance record, optimize its balance sheet, execute on strategic transactions and commercialize products.”
Crowley said, “I am thankful for being part of the Lantheus team that has both grown the company into one of the market leaders it is today and positioned it well for its next stage of growth. I am confident the company is in a strong position moving forward.”
Lantheus Holdings Inc. is the parent company of LMI, a developer, manufacturer, and commercializer of diagnostic imaging agents and products. LMI provides a portfolio of products, including the echocardiography contrast agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The company is headquartered in North Billerica, Mass., with offices in Puerto Rico and Canada.